Document Detail

Alveolar-capillary membrane permeability for early prediction of response of inhaled steroid on patients with chronic obstructive pulmonary disease.
MedLine Citation:
PMID:  16882106     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND OBJECTIVE: Glucocorticosteroid reversibility-testing is undertaken over a period of 3 months to identify whether patients with chronic obstructive pulmonary disease (COPD) would benefit from long-term inhaled corticosteroids. This study assessed whether alveolar-capillary membrane (a/c) permeability testing can be used as an early alternative test method for the same purpose. METHODS: Fourteen patients with severe and symptomatic moderate COPD (group S) were prescribed inhaled steroid 800 microg/day for 3 months. Before inhalation and 4 weeks after inhalation therapy, forced expiratory volume in 1 s (FEV(1)) and a/c permeability using (99m)Tc-DTPA were performed. FEV(1) was recorded again at the end of the third month. Another 10 patients with COPD of comparable severity (group B) prescribed with inhaled bronchodilators were examined and studied as controls. RESULTS: In group S, the permeability decreased in eight patients (group D) and increased in six patients (group I). No significant change was noted in FEV(1) at the end of the first month. However, seven patients in group D showed significant improvement in FEV(1) at the end of the third month, whereas in patients in group I no significant changes were observed. In group B, no significant change in a/c permeability was observed, although the FEV(1) increased by 12-17%. CONCLUSION: With steroid inhalation, the a/c permeability at 4 weeks predicts future changes in lung functions. Long-term inhaled corticosteroids are likely to be useful if permeability decreases. This test, which needs further validation, appears to provide much earlier prediction of response than glucocorticoid reversibility testing.
S-H Chou; Y-W Chen; H-Y Chuang; E-L Kao; M-F Huang
Related Documents :
12197896 - Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy. long-term ...
7783536 - Prevention of relapses in systemic lupus erythematosus.
2563226 - Infectious complications of cyclophosphamide treatment for vasculitis.
10155546 - Recovery of both acute massive pulmonary hemorrhage and acute renal failure in a system...
12757066 - A controlled trial of a new treatment for galactocele.
25233346 - Efficacy and safety of amphotericin b emulsion versus liposomal formulation in indian p...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of clinical pharmacy and therapeutics     Volume:  31     ISSN:  0269-4727     ISO Abbreviation:  J Clin Pharm Ther     Publication Date:  2006 Aug 
Date Detail:
Created Date:  2006-08-02     Completed Date:  2006-11-21     Revised Date:  2008-05-28    
Medline Journal Info:
Nlm Unique ID:  8704308     Medline TA:  J Clin Pharm Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  363-8     Citation Subset:  IM    
Department of Surgery, Kaohsiung Medical University, Kaohsiung, Taiwan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Inhalation
Adrenal Cortex Hormones / administration & dosage,  pharmacology,  therapeutic use*
Bronchodilator Agents / pharmacology,  therapeutic use
Case-Control Studies
Cell Membrane Permeability / drug effects
Forced Expiratory Volume / drug effects
Middle Aged
Pulmonary Disease, Chronic Obstructive / classification,  drug therapy*
Severity of Illness Index
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Bronchodilator Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Benchmarking the current dispensing rate of Welsh hospital pharmacies.
Next Document:  Pharmacotherapeutic management of COPD patients in Greece--adherence to international guidelines.